XML 131 R110.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019
Segment Reporting Information [Line Items] |  |  |
Sales | $ 48,704 | $ 41,518 | $ 39,121
Revenue related to the sale of the marketing rights | 185 |  |
Operating Segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 48,322 | 41,336 | 38,668
Operating Segments | Pharmaceutical segment |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 42,754 | 36,610 | 34,100
Operating Segments | Pharmaceutical segment | Keytruda |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 17,186 | 14,380 | 11,084
Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 989 | 725 | 444
Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 704 | 580 | 404
Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 5,673 | 3,938 | 3,737
Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,135 | 1,878 | 2,275
Operating Segments | Pharmaceutical segment | Pneumovax 23 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 893 | 1,087 | 926
Operating Segments | Pharmaceutical segment | RotaTeq |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 807 | 797 | 791
Operating Segments | Pharmaceutical segment | Vaqta |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 179 | 170 | 238
Operating Segments | Pharmaceutical segment | Bridion |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,532 | 1,198 | 1,131
Operating Segments | Pharmaceutical segment | Prevymis |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 370 | 281 | 165
Operating Segments | Pharmaceutical segment | Primaxin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 259 | 251 | 273
Operating Segments | Pharmaceutical segment | Noxafil |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 259 | 329 | 662
Operating Segments | Pharmaceutical segment | Cancidas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 212 | 213 | 249
Operating Segments | Pharmaceutical segment | Invanz |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 202 | 211 | 263
Operating Segments | Pharmaceutical segment | Zerbaxa |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | (1) | 130 | 121
Operating Segments | Pharmaceutical segment | Simponi |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 825 | 838 | 830
Operating Segments | Pharmaceutical segment | Remicade |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 299 | 330 | 411
Operating Segments | Pharmaceutical segment | Belsomra |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 318 | 327 | 306
Operating Segments | Pharmaceutical segment | Molnupiravir |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 952 | 0 | 0
Operating Segments | Pharmaceutical segment | Isentress/Isentress HD |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 769 | 857 | 975
Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 342 | 281 | 204
Operating Segments | Pharmaceutical segment | Adempas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 252 | 220 | 215
Operating Segments | Pharmaceutical segment | Januvia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 3,324 | 3,306 | 3,482
Operating Segments | Pharmaceutical segment | Janumet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,964 | 1,971 | 2,041
Operating Segments | Pharmaceutical segment | Other pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,310 | 2,312 | 2,873
Operating Segments | Animal Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 5,568 | 4,703 | 4,393
Operating Segments | Animal Health | Livestock |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 3,295 | 2,939 | 2,784
Operating Segments | Animal Health | Companion Animals |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,273 | 1,764 | 1,609
Operating Segments | Other segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 23 | 175
Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 382 | 182 | 453
United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 22,425 | 19,588 | 18,420
United States | Operating Segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 22,159 | 19,517 | 18,334
United States | Operating Segments | Pharmaceutical segment |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 20,401 | 18,010 | 16,854
United States | Operating Segments | Pharmaceutical segment | Keytruda |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 9,765 | 8,352 | 6,305
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 515 | 417 | 269
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 417 | 359 | 239
United States | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,881 | 1,755 | 1,831
United States | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,629 | 1,378 | 1,683
United States | Operating Segments | Pharmaceutical segment | Pneumovax 23 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 547 | 727 | 679
United States | Operating Segments | Pharmaceutical segment | RotaTeq |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 473 | 486 | 506
United States | Operating Segments | Pharmaceutical segment | Vaqta |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 100 | 103 | 130
United States | Operating Segments | Pharmaceutical segment | Bridion |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 762 | 583 | 533
United States | Operating Segments | Pharmaceutical segment | Prevymis |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 153 | 119 | 84
United States | Operating Segments | Pharmaceutical segment | Primaxin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2 | 2 | 2
United States | Operating Segments | Pharmaceutical segment | Noxafil |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 60 | 42 | 282
United States | Operating Segments | Pharmaceutical segment | Cancidas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 4 | 7 | 6
United States | Operating Segments | Pharmaceutical segment | Invanz |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | (5) | 9 | 30
United States | Operating Segments | Pharmaceutical segment | Zerbaxa |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 4 | 74 | 63
United States | Operating Segments | Pharmaceutical segment | Simponi |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Remicade |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Belsomra |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 78 | 81 | 92
United States | Operating Segments | Pharmaceutical segment | Molnupiravir |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 632 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 294 | 326 | 398
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 312 | 259 | 194
United States | Operating Segments | Pharmaceutical segment | Adempas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 0
United States | Operating Segments | Pharmaceutical segment | Januvia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,404 | 1,470 | 1,724
United States | Operating Segments | Pharmaceutical segment | Janumet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 367 | 477 | 589
United States | Operating Segments | Pharmaceutical segment | Other pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,007 | 984 | 1,215
United States | Operating Segments | Animal Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,758 | 1,484 | 1,306
United States | Operating Segments | Animal Health | Livestock |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 667 | 612 | 582
United States | Operating Segments | Animal Health | Companion Animals |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,091 | 872 | 724
United States | Operating Segments | Other segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 23 | 174
United States | Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 266 | 71 | 86
Int’l |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 26,279 | 21,930 | 20,701
Int’l | Operating Segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 26,163 | 21,819 | 20,333
Int’l | Operating Segments | Pharmaceutical segment |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 22,353 | 18,600 | 17,246
Int’l | Operating Segments | Pharmaceutical segment | Keytruda |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 7,421 | 6,028 | 4,779
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 473 | 308 | 176
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 287 | 220 | 165
Int’l | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 3,792 | 2,184 | 1,905
Int’l | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 506 | 500 | 592
Int’l | Operating Segments | Pharmaceutical segment | Pneumovax 23 |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 346 | 359 | 247
Int’l | Operating Segments | Pharmaceutical segment | RotaTeq |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 334 | 311 | 284
Int’l | Operating Segments | Pharmaceutical segment | Vaqta |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 79 | 67 | 108
Int’l | Operating Segments | Pharmaceutical segment | Bridion |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 770 | 615 | 598
Int’l | Operating Segments | Pharmaceutical segment | Prevymis |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 218 | 162 | 81
Int’l | Operating Segments | Pharmaceutical segment | Primaxin |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 258 | 248 | 271
Int’l | Operating Segments | Pharmaceutical segment | Noxafil |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 199 | 287 | 380
Int’l | Operating Segments | Pharmaceutical segment | Cancidas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 208 | 207 | 242
Int’l | Operating Segments | Pharmaceutical segment | Invanz |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 207 | 202 | 233
Int’l | Operating Segments | Pharmaceutical segment | Zerbaxa |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | (5) | 56 | 58
Int’l | Operating Segments | Pharmaceutical segment | Simponi |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 825 | 838 | 830
Int’l | Operating Segments | Pharmaceutical segment | Remicade |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 299 | 330 | 411
Int’l | Operating Segments | Pharmaceutical segment | Belsomra |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 241 | 247 | 214
Int’l | Operating Segments | Pharmaceutical segment | Molnupiravir |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 320 | 0 | 0
Int’l | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 474 | 531 | 576
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 30 | 22 | 10
Int’l | Operating Segments | Pharmaceutical segment | Adempas |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 252 | 220 | 215
Int’l | Operating Segments | Pharmaceutical segment | Januvia |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,920 | 1,836 | 1,758
Int’l | Operating Segments | Pharmaceutical segment | Janumet |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,597 | 1,494 | 1,452
Int’l | Operating Segments | Pharmaceutical segment | Other pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,302 | 1,328 | 1,661
Int’l | Operating Segments | Animal Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 3,810 | 3,219 | 3,086
Int’l | Operating Segments | Animal Health | Livestock |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 2,628 | 2,327 | 2,201
Int’l | Operating Segments | Animal Health | Companion Animals |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 1,182 | 892 | 885
Int’l | Operating Segments | Other segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | 0 | 0 | 1
Int’l | Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales | $ 116 | $ 111 | $ 368

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_MolnupiravirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |